TY - JOUR
T1 - Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas
AU - Kim, Jennifer E.
AU - Patel, Mira A.
AU - Mangraviti, Antonella
AU - Kim, Eileen S.
AU - Theodros, Debebe
AU - Velarde, Esteban
AU - Liu, Ann
AU - Sankey, Eric W.
AU - Tam, Ada
AU - Xu, Haiying
AU - Mathios, Dimitrios
AU - Jackson, Christopher M.
AU - Harris-Bookman, Sarah
AU - Garzon-Muvdi, Tomas
AU - Sheu, Mary
AU - Martin, Allison M.
AU - Tyler, Betty M.
AU - Tran, Phuoc T.
AU - Ye, Xiaobu
AU - Olivi, Alessandro
AU - Taube, Janis M.
AU - Burger, Peter C.
AU - Drake, Charles G.
AU - Brem, Henry
AU - Pardoll, Drew M.
AU - Lim, Michael
N1 - Publisher Copyright:
© 2016 American Association for Cancer Research.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Purpose: Checkpoint molecules like programmed death-1 (PD-1) and T-cell immunoglobulin mucin-3 (TIM-3) are negative immune regulators that may be upregulated in the setting of glioblastoma multiforme. Combined PD-1 blockade and stereotactic radiosurgery (SRS) have been shown to improve antitumor immunity and produce long-term survivors in a murine glioma model. However, tumor-infiltrating lymphocytes (TIL) can express multiple checkpoints, and expression of ≥2 checkpoints corresponds to a more exhausted T-cell phenotype. We investigate TIM-3 expression in a glioma model and the antitumor efficacy of TIM-3 blockade alone and in combination with anti-PD-1 and SRS. Experimental Design: C57BL/6 mice were implanted with murine glioma cell line GL261-luc2 and randomized into 8 treatment arms: (i) control, (ii) SRS, (iii) anti-PD-1 antibody, (iv) anti-TIM-3 antibody, (v) anti-PD-1 + SRS, (vi) anti-TIM-3 + SRS, (vii) anti-PD-1 + anti-TIM-3, and (viii) anti-PD-1 + anti-TIM-3 + SRS. Survival and immune activation were assessed. Results: Dual therapy with anti-TIM-3 antibody + SRS or anti-TIM-3 + anti-PD-1 improved survival compared with anti-TIM-3 antibody alone. Triple therapy resulted in 100% overall survival (P < 0.05), a significant improvement compared with other arms. Long-term survivors demonstrated increased immune cell infiltration and activity and immune memory. Finally, positive staining for TIM-3 was detected in 7 of 8 human GBM samples. Conclusions: This is the first preclinical investigation on the effects of dual PD-1 and TIM-3 blockade with radiation. We also demonstrate the presence of TIM-3 in human glioblastoma multiforme and provide preclinical evidence for a novel treatment combination that can potentially result in long-term glioma survival and constitutes a novel immunotherapeutic strategy for the treatment of glioblastoma multiforme.
AB - Purpose: Checkpoint molecules like programmed death-1 (PD-1) and T-cell immunoglobulin mucin-3 (TIM-3) are negative immune regulators that may be upregulated in the setting of glioblastoma multiforme. Combined PD-1 blockade and stereotactic radiosurgery (SRS) have been shown to improve antitumor immunity and produce long-term survivors in a murine glioma model. However, tumor-infiltrating lymphocytes (TIL) can express multiple checkpoints, and expression of ≥2 checkpoints corresponds to a more exhausted T-cell phenotype. We investigate TIM-3 expression in a glioma model and the antitumor efficacy of TIM-3 blockade alone and in combination with anti-PD-1 and SRS. Experimental Design: C57BL/6 mice were implanted with murine glioma cell line GL261-luc2 and randomized into 8 treatment arms: (i) control, (ii) SRS, (iii) anti-PD-1 antibody, (iv) anti-TIM-3 antibody, (v) anti-PD-1 + SRS, (vi) anti-TIM-3 + SRS, (vii) anti-PD-1 + anti-TIM-3, and (viii) anti-PD-1 + anti-TIM-3 + SRS. Survival and immune activation were assessed. Results: Dual therapy with anti-TIM-3 antibody + SRS or anti-TIM-3 + anti-PD-1 improved survival compared with anti-TIM-3 antibody alone. Triple therapy resulted in 100% overall survival (P < 0.05), a significant improvement compared with other arms. Long-term survivors demonstrated increased immune cell infiltration and activity and immune memory. Finally, positive staining for TIM-3 was detected in 7 of 8 human GBM samples. Conclusions: This is the first preclinical investigation on the effects of dual PD-1 and TIM-3 blockade with radiation. We also demonstrate the presence of TIM-3 in human glioblastoma multiforme and provide preclinical evidence for a novel treatment combination that can potentially result in long-term glioma survival and constitutes a novel immunotherapeutic strategy for the treatment of glioblastoma multiforme.
UR - http://www.scopus.com/inward/record.url?scp=85010297255&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85010297255&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-15-1535
DO - 10.1158/1078-0432.CCR-15-1535
M3 - Article
C2 - 27358487
AN - SCOPUS:85010297255
SN - 1078-0432
VL - 23
SP - 124
EP - 136
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 1
ER -